Moleculin Biotech - MBRX

10/20/2026

In a new episode of CEO Corner, Moleculin Chairman and CEO Walter Klemp discusses the progress of the Company’s Phase 2/3 MIRACLE trial evaluating Annamycin in combination with high-dose cytarabine (HiDAC) for patients with second-line relapsed or refractory acute myeloid leukemia (AML). Watch the full episode here: https://bit.ly/4uoTtkU

10/20/2026

In the latest CEO Corner, Moleculin Biotech CEO, Walter Klemp, discusses continued progress in the Phase 2/3 MIRACLE trial evaluating Annamycin in combination with high-dose cytarabine for patients with relapsed or refractory acute myeloid leukemia.

The discussion highlights the completion of enrollment in Part A, encouraging interim efficacy results and Annamycin’s potential to address treatment resistance and cardiac safety concerns associated with conventional anthracyclines. He also outlines anticipated milestones, including the full 90-patient Part A data readout expected in Q1 2027 and next steps toward the pivotal Part B expansion.

Watch the latest CEO Corner: https://vimeo.com/1237416283/633b2f47df?share=copy&fl=sv&fe=ci

Moleculin Biotech Chairman and CEO Walter Klemp discusses the progress of the Company’s Phase 2/3 MIRACLE trial evaluating Annamycin in combination with high-dose cytarabine (HiDAC) for patients with second-line relapsed or refractory acute myeloid leukemia (AML).

10/20/2026

In the latest CEO Corner, Moleculin Biotech CEO, Walter Klemp, discusses continued progress in the Phase 2/3 MIRACLE trial evaluating Annamycin in combination with high-dose cytarabine for patients with relapsed or refractory acute myeloid leukemia.

The discussion highlights the completion of enrollment in Part A, encouraging interim efficacy results and Annamycin’s potential to address treatment resistance and cardiac safety concerns associated with conventional anthracyclines. He also outlines anticipated milestones, including the full 90-patient Part A data readout expected in Q1 2027 and next steps toward the pivotal Part B expansion.

Watch the latest CEO Corner: https://bit.ly/4jwY15U

About Management Board of Directors Scientific Advisory Board Partnership Inquiries CEO Corner Vision. Insight. Access. Episode 4 Moleculin Biotech Chairman and CEO Walter Klemp discusses the progress of the Company’s Phase 2/3 MIRACLE trial evaluating Annamycin in combination with high-dose cytar...

10/20/2026

In Moleculin’s latest CEO Corner, Walter Klemp discusses progress in the Phase 2/3 MIRACLE trial evaluating Annamycin in R/R AML, including Part A enrollment completion, interim efficacy results and the anticipated Q1 2027 data readout. Watch here: https://bit.ly/4uoTtkU

10/16/2026

Moleculin Biotech Announces Reverse Stock Split: https://bit.ly/4yti1tY

10/16/2026

ICYMI: showcased Annamycin data at the AACR Conference on Pancreatic Cancer, highlighting research into its antitumor activity in pancreatic cancer.

10/13/2026

Moleculin will present at the Maxim Growth Summit on October 14 at 9:00 AM ET as part of the Oncology Panel.

Tune in for a discussion on developments and opportunities across the oncology landscape.

10/09/2026

We’re heading to New York!

We are participating in the 2026 Maxim Growth Summit, October 13-14 in New York City. We look forward to connecting with investors and sharing more about our progress advancing Annamycin.

10/07/2026

Walter Klemp, Chairman and CEO of Moleculin, will present at the 2026 Maxim Growth Summit Advances in Oncology Panel on Wednesday, October 14, 2026, at 9:00 AM ET, in New York, NY. For details: https://bit.ly/47b8xrZ

10/02/2026

What makes Annamycin different?

is advancing potential highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and eliminate the cardiotoxicity common with currently prescribed anthracyclines.